SML3679

SLM6031434 hydrochloride

≥98% (HPLC)

• 别名: (2S)-2-[3-[4-(Octyloxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-1-pyrrolidinecarboximidamide, hydrochloride, (S)-2-(3-(4-(Octyloxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidine-1-carboximidamide, hydrochloride, (S)-Amino(2-(3-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyrrolidin-1-yl)methaniminium chloride, SLM 6031434 HCl, SLM 6081442 (S)-enantiomer HCl, SLM-6031434 HCl, SLM-6081442 (S)-enantiomer HCl, SLM6081442 (S)-enantiomer HCl
• 经验公式（希尔记法）: C₂₂H₃₀F₃N₅O₂·HCl
• CAS号: 1897379-34-8
• 分子量: 489.96
• MDL號碼: MFCD31689247
• 分類程式碼代碼: 51111800
• 分類程式碼代碼: 12352200
• NACRES: NA.21

属性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 儲存條件: desiccated
• 顏色: white to beige
• 溶解度: water: ≥2 mg/mL
• 儲存溫度: -10 to -25°C

说明

生化／生理作用

SLM6031434 is a selective sphingosine (Sph) kinase 2 (SK2, SphK2, SpK2) inhibitor (r/m SphK2 Ki = 400/500 nM, r/m SphK1 Ki >20 μM) that effectively downregulates cellular sphingosine 1-phosphate (S1P) level (47% S1P & 143% Sph of control in U937 post 2h 100 nM SLM6031434 treatment) and selectively reduces plasma S1P in Sphk1-/-, but not Sphk2-/- mice in vivo (5 mg/kg i.v.). In contrary to Sphk2-KO mice, SLM6031434 treatment enhances plasma S1P in wild-type mice and offers neuroprotective efficacy against ischemic stroke (2 mg/kg i.v. 2h prior to tMCAO).

注意

Hygroscopic

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable